BioPorto A/S (THOXF PINK) stock market data APIs
$0.1496
0(0%)
as of January 30, 2026
Try our APIs with
free plan!
BioPorto A/S Financial Data Overview
Price chart is built with
Anychart
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
Prev. Close
0.1496
Open
0.1496
High
0.1496
Low
0.1496
52 wk Range
0.149-0.31
Market Cap
73 769 K
Shares Outstanding
495 M
Revenue
36 561 K
EPS
-0.008
Beta
1.204
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioPorto A/S data using free add-ons & libraries
Get BioPorto A/S Fundamental Data
BioPorto A/S Fundamental data includes:
- Net Revenue: 36 561 K
- EBITDA: -86 539 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioPorto A/S News
New
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
BioPorto A/S August 28, 2025 News Release ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche ...
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
BioPorto A/S June 27, 2025 Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – Bio...
BioPorto Announces Interim Results for the First Six Months of 2023
BioPorto A/S August 1, 2023 Announcement no. 14 BioPorto Announces Interim Results for the First Six Months of 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, August 1, 2023, (GLOBE NEWSWIRE) -- Bio...
BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call
BioPorto A/S July 7, 2023 News Release BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call COPENHAGEN, Denmark and BOSTON, MA, USA, July 7, 2023, (GLOBE NEWSWIRE) -- BioPort...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
